Free Trial

Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

-1.35 (-3.49%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.98 million shs
Average Volume
1.16 million shs
Market Capitalization
$5.45 billion
P/E Ratio
Dividend Yield
Price Target

Ionis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
59.3% Upside
$59.54 Price Target
Short Interest
6.53% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.93mentions of Ionis Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$422,910 Sold Last Quarter
Proj. Earnings Growth
From ($3.96) to ($3.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Medical Sector

71st out of 921 stocks

Pharmaceutical Preparations Industry

23rd out of 416 stocks

IONS stock logo

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

IONS Stock Price History

IONS Stock News Headlines

TKO Group: Q1 Earnings Snapshot
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Q1 2024 Ionis Pharmaceuticals Inc Earnings Call
IONS Quantitative Stock Analysis
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$788 million
Book Value
$2.70 per share


Free Float
Market Cap
$5.55 billion
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

IONS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IONS shares.
View IONS analyst ratings
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price target for 2024?

14 Wall Street analysts have issued 1-year target prices for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $28.00 to $82.00. On average, they anticipate the company's share price to reach $59.54 in the next year. This suggests a possible upside of 59.3% from the stock's current price.
View analysts price targets for IONS
or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2024?

Ionis Pharmaceuticals' stock was trading at $50.59 at the beginning of 2024. Since then, IONS stock has decreased by 26.1% and is now trading at $37.37.
View the best growth stocks for 2024 here

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our IONS earnings forecast

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.12. The business had revenue of $119 million for the quarter, compared to analysts' expectations of $131.42 million. Ionis Pharmaceuticals had a negative net margin of 49.49% and a negative trailing twelve-month return on equity of 107.64%. The firm's revenue for the quarter was down 9.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.87) EPS.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $618.1 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Bellevue Group AG (5.69%), Clearbridge Investments LLC (3.06%), Price T Rowe Associates Inc. MD (2.41%), Jacobs Levy Equity Management Inc. (0.39%) and Baillie Gifford & Co. (0.20%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Baroldi, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen.
View institutional ownership trends

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IONS) was last updated on 5/21/2024 by Staff

From Our Partners